Cargando…
Evaluation of Low-Molecular-Weight Heparin for Treatment of Portal Vein Thrombosis in Liver Cirrhosis Patients
Background and Objectives: Even though low-molecular-weight heparin (LMWH), including dalteparin, has a critical role in portal vein thrombosis (PVT) treatment in liver cirrhosis (LC) patients, the predictive factors and the proper dose of dalteparin for PVT treatment and relapse have not yet been i...
Autores principales: | Han, Ji Min, Koh, Youngil, Kim, Sung Hwan, Suh, Sung Yun, Cho, Yoon Sook, Lee, Jeong-Hoon, Yu, Su Jong, Yoon, Jung-Hwan, Gwak, Hye Sun |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9965161/ https://www.ncbi.nlm.nih.gov/pubmed/36837493 http://dx.doi.org/10.3390/medicina59020292 |
Ejemplares similares
-
Portal vein thrombosis in patients with cirrhosis
por: von Köckritz, Leona, et al.
Publicado: (2017) -
Transient portal vein thrombosis in liver cirrhosis
por: Qi, Xingshun, et al.
Publicado: (2018) -
Portal Vein Thrombosis in Decompensated Cirrhosis: Rationale for Treatment
por: Senzolo, Marco, et al.
Publicado: (2019) -
Controversies in the Management of Portal Vein Thrombosis in Liver Cirrhosis
por: Mancuso, Andrea
Publicado: (2020) -
Acute portal vein thrombosis with COVID-19 and cirrhosis
por: Miyazato, Yusuke, et al.
Publicado: (2021)